

CURRENT REPORT 37/2021

December 14, 2021

Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("**Company**", "**Ryvu**") hereby informs, in connection with the current stock report RB no 7/2020 dated 16th of April 2020, that the Company has received yesterday a notice from Galapagos NV with its registered office in Mechelen, Belgium ("**Galapagos**"), indicating that Galapagos has chosen to exercise its option under the Option, License and Research Collaboration Agreement ("**Agreement**"), to obtain an exclusive license to continue the research, development and commercialization of the program with therapeutic potential in inflammatory diseases based on compounds discovered and developed by Ryvu. Upon execution of the option Ryvu is eligible to receive an option exercise fee in the amount of EUR 1,250,000 (PLN 5,775,500 converted at the rate of NBP from 13th of December 2021, EUR 1 = PLN 4.6204) and is eligible to receive research and development milestone payments, as well as royalties on future sales.

The joint research collaboration under the Agreement was focused on the discovery and development of novel small molecule drugs in the area of inflammation, with Ryvu responsible for the early drug discovery. The collaboration was based on a novel drug target identified initially by Ryvu and was driven by the joint effort of scientific teams from both companies, supported by the Ryvu's resources and expertise in high-throughput screening, medicinal chemistry and biology.

Legal basis: Article 17 (1) of the Market Abuse Regulation (MAR) – confidential information.

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Tomasz Nocuń – Proxy